Skip to content

The clinical trial program of Cong Rongjing in treating early-stage Parkinson's disease

Study on the neuroprotective mechanism of compound Cong-Rongjing to GDNF and observation on the effect of early-stage Parkinson's disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16008394
Enrollment
Unknown
Registered
2016-04-30
Start date
2016-07-01
Completion date
Unknown
Last updated
2018-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pakinson's Dissease

Interventions

Intervention Group:Sifrol/XI Ning+compound Cong Rongjing
Control Group:Sifrol/XI Ning+placebo

Sponsors

Fujian University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients meeting the diagnostic criteria of PD; 2. meeting the TCM pattern criteria of deficiency of marrow-reservoir; 3. meeting the classification criteria of PD (Early-stage PD patients; The stage of Hoehn&Yahr Scale is between 1-2.5 levels.); 4. aged between 50 and 70; 5. receive the treatments voluntarily and sign informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with Parkinsons syndrome and Parkinsonism-plus syndrome or other non-PD patients; 2. MRI scanning contraindication; 3. With abnormal signal shadow of conventional MRI scan(does not rule out the lacunar infarction); 4. With history of limb trauma, neuromuscular junction and muscle disease; With head injury, long-term exposure to chemicals and other diseases; 5. serious heart,liver or kidney diseases,diabetes,mental and neurological disorders, severe infection, tumour, encephalitis, and so on. Allergic to the treatment drug. 6. aking the western medication of PD, but the the time interval from last time taking medication to the visit is less than 7 days; Taking traditional Chinese medication of PD, but the the time interval from last time ttaking medication to the visit is less than 3 months; 7. patients have already participated in other clinical intervention research program in the past 3 months.

Design outcomes

Primary

MeasureTime frame
Unified Parkinson's Disease Rating Scale;

Secondary

MeasureTime frame
Hoehn-Yahr Rating Scale;Parkinson Disease Question-39;TCM(traditional chinese medicine) symptoms rating scale;change of medication’s dosage;The content of alpha -Synuclein and phosphorylated alpha -Synuclein in the patients' plasma;

Countries

China

Contacts

Public ContactCai Jing

Fujian University of Traditional Chinese Medicine

caij1@163.com+86 13110770937

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 27, 2026